Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Doxepin Alone or Combined With Ramelteon Versus Placebo for Improving Sleep Quality After Primary Total Knee Arthroplasty

13 de mayo de 2026 actualizado por: Nick Hernandez, University of Washington

Doxepin Versus Doxepin and Ramelteon Versus Placebo to Improve Sleep Quality After Primary Total Knee Arthroplasty: A Randomized Controlled Trial

Many patients experience poor sleep during recovery after total knee arthroplasty (TKA). Disturbed sleep can last weeks to months and may worsen pain, slow healing, and reduce overall quality of life. Few safe, effective, evidence-based options exist to improve sleep during this recovery period. This study aims to determine whether the medications doxepin, either alone or in combination with ramelteon, can improve sleep quality during early recovery after TKA. The investigators will also evaluate whether improved sleep leads to better pain control, knee function, and overall quality of life.

Descripción general del estudio

Descripción detallada

This randomized, placebo-controlled clinical trial seeks to answer the following question: Is doxepin or combination therapy consisting of doxepin plus ramelteon superior to placebo in terms of (1) sleep quality as measured by the Insomnia Severity Index, (2) postoperative knee function as measured by KOOS-JR, KOOS-PS, or (3) overall health-related quality of life during the first three months after total knee arthroplasty.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

129

Fase

  • Fase 4

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Gerald Y Liao, MS
  • Número de teléfono: 617-710-7211
  • Correo electrónico: liaog@uw.edu

Copia de seguridad de contactos de estudio

  • Nombre: Nicholas M Hernandez, MD
  • Número de teléfono: 530-514-1275
  • Correo electrónico: nichern@uw.edu

Ubicaciones de estudio

    • Washington
      • Seattle, Washington, Estados Unidos, 98133
        • University of Washington Medical Center Hip & Knee Center
        • Contacto:
          • Portia Morgan
          • Número de teléfono: 206-668-3674
          • Correo electrónico: morganp9@uw.edu
        • Investigador principal:
          • Nicholas M Hernandez, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Those receiving primary total knee arthroplasty (TKA)
  • 80 years or less, age 18 or greater

Exclusion Criteria:

  • History of cardiovascular bundle branch block
  • Actively taking selecrtive serotoin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), or having treatment via counseling/psychotherapy for major depression or anxiety, bipolar, or psychotic disorder
  • Pre-operative narcotics (defined as more than 1 prescription in the past 3 months)
  • Self-reported use of alcohol in excess of >2 drinks/day (in men) and > 1 drink/day (in women)
  • Use of prescription sleep aids (e.g., Ambien, Trazadone) prior to surgery (i.e., melatonin or other OTC sleep aids are permitted)
  • History of major sleep disorder (e.g., obstructive sleep apnea (OSA), restless leg syndrome, narcolepsy)
  • Pregnant, breastfeeding or planning to become pregnant in the next 3 months post-surgery. No pregnancy testing will be performed; screening will rely solely on participant self-report.
  • Unable to take the study medication(s) due to contraindications with other medications the patient uses
  • Have been diagnosed with (or are at risk of) narrow-angle or angle-closure glaucoma. In order to be eligible, participants must be able to report that they have had their eyes dilated within the past year without problems.
  • Have severe urinary retention or difficulty emptying your bladder.
  • Had glaucoma-related eye procedures (e.g., laser iridotomy)
  • Ongoing use of glaucoma eye drops.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Doxepin 6 mg
Participants receive doxepin 6 mg and matching placebo orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Experimental: Doxepin 6 mg and Ramelteon 8mg
Participants receive doxepin 6 mg and ramelteon 8 mg orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Doxepin 6 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Ramelteon 8 mg administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty
Comparador de placebos: Placebo
Participants receive 2 matching placebos orally once nightly for sleep during the first 6 weeks postoperative period following total knee arthroplasty.
Placebo administered orally once nightly for sleep during the first 6 weeks of the postoperative period following total knee arthroplasty

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Insomnia Severity Index (ISI) scores (sleep quality)
Periodo de tiempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Insomnia Severity Index (ISI) The Insomnia Severity Index is a 7-item self-reported questionnaire assessing the nature, severity, and impact of insomnia.

  • Score range: 0 to 28
  • Interpretation: Higher scores indicate worse insomnia severity

Score categories:

  • 0-7: No clinically significant insomnia
  • 8-14: Subthreshold insomnia
  • 15-21: Clinical insomnia (moderate severity)
  • 22-28: Clinical insomnia (severe)
Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS)
Periodo de tiempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.

Knee Injury and Osteoarthritis Outcome Score Physical Function Short Form (KOOS-PS):

The KOOS-PS is a 7-item patient-reported outcome measure assessing knee-related physical function, including activities such as rising from bed, putting on socks, rising from sitting, bending to the floor, twisting/pivoting, kneeling, and squatting . Each item is scored on a 5-point Likert scale (None to Extreme). Scores are transformed to a normalized scale ranging from 0 to 100, with higher scores indicating worse physical function (greater disability).

Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively.
Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR)
Periodo de tiempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS-JR):

The KOOS-JR is a patient-reported outcome measure assessing knee pain, stiffness, and functional limitations during activities of daily living over the past week, including tasks such as twisting/pivoting, stair navigation, standing, rising from sitting, and bending . The instrument consists of 7 items scored on a 5-point Likert scale (None to Extreme). Raw scores (range 0-28) are summed and converted to an interval score ranging from 0 to 100, where 0 represents total knee disability and 100 represents perfect knee health (higher scores indicate better outcomes)

Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively
Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10)
Periodo de tiempo: Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10):

The PROMIS-10 is a 10-item patient-reported outcome measure assessing global physical health, mental health, pain, fatigue, and social functioning. Items are scored on 5-point Likert scales (e.g., Excellent to Poor; Not at all to Very much), with one pain item scored from 0 to 10. Raw scores are summed and converted to standardized T-scores for Global Physical Health and Global Mental Health, each ranging approximately from 0 to 100 (mean 50, standard deviation 10), where higher scores indicate better health status

Baseline; 2 weeks postoperatively; 6 weeks postoperatively; 3 months postoperatively

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
90-Day Hospital Readmission Status
Periodo de tiempo: Within 90 days postoperatively
Hospital readmission status within 90 days following primary total knee arthroplasty, defined as any unplanned inpatient admission to a hospital occurring within 90 days after the index procedure. This is a dichotomous outcome (Yes/No), where "Yes" indicates that a readmission occurred and represents a worse outcome.
Within 90 days postoperatively
Medication Compliance
Periodo de tiempo: 2 weeks postoperatively; 6 weeks postoperatively

Medication Compliance:

Medication adherence assessed using patient self-report and pill counts when feasible. Self-reported adherence is measured by patient-reported proportion of prescribed doses taken, and pill counts are used to calculate the percentage of medication consumed relative to the prescribed amount. Adherence is expressed as a percentage from 0 to 100%, where higher values indicate better compliance.

2 weeks postoperatively; 6 weeks postoperatively
Length of Stay (LOS)
Periodo de tiempo: Perioperative/Periprocedural

Length of Stay (LOS):

Length of hospital stay following primary total knee arthroplasty, defined as the number of days from hospital admission to discharge (continuous variable, ≥0 days), where higher values indicate longer hospitalization (worse outcome).

Perioperative/Periprocedural
Discharge Destination
Periodo de tiempo: Perioperative/Periprocedural

Discharge Destination:

Discharge disposition following primary total knee arthroplasty, categorized as home versus skilled nursing facility. This is a categorical outcome where discharge to a skilled nursing facility represents a worse outcome compared to discharge home.

Perioperative/Periprocedural
Postoperative Mobility (Step Count)
Periodo de tiempo: Perioperative/Periprocedural

Postoperative Mobility (Step Count):

Postoperative mobility assessed by the number of steps taken during inpatient physical therapy sessions following primary total knee arthroplasty. Step count is recorded as the total number of steps ambulated (continuous variable, ≥0), where higher values indicate better functional recovery.

Perioperative/Periprocedural
Level of Assistance Required for Ambulation
Periodo de tiempo: Perioperative/Periprocedural

Level of Assistance Required for Ambulation:

Level of assistance required during inpatient physical therapy following primary total knee arthroplasty, categorized as independent, 1-person assist, 2-person assist, or maximal assist. This is an ordinal outcome where greater assistance requirements indicate worse functional recovery.

Perioperative/Periprocedural
Postoperative Falls
Periodo de tiempo: Perioperative/Periprocedural; 3 months postoperatively
Postoperative Falls: Occurrence of patient falls during hospitalization or within the follow-up period after primary total knee arthroplasty, defined as any unintentional descent to the ground or lower level documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a fall occurred and represents a worse outcome.
Perioperative/Periprocedural; 3 months postoperatively
Postoperative Delirium
Periodo de tiempo: Perioperative/Periprocedural; 3 months postoperatively
Occurrence of delirium during hospitalization or follow-up after primary total knee arthroplasty, defined by clinical documentation of acute confusional state or use of delirium-related precautions (e.g., 1:1 sitter, physical restraints). This is a dichotomous outcome (Yes/No), where "Yes" indicates delirium occurred and represents a worse outcome.
Perioperative/Periprocedural; 3 months postoperatively
Pressure Ulcers (Bed Sores)
Periodo de tiempo: Perioperative/Periprocedural; 3 months postoperatively

Pressure Ulcers (Bed Sores):

Development of pressure ulcers during hospitalization or follow-up after primary total knee arthroplasty, defined as localized injury to the skin or underlying tissue documented in the medical record. This is a dichotomous outcome (Yes/No), where "Yes" indicates a pressure ulcer occurred and represents a worse outcome.

Perioperative/Periprocedural; 3 months postoperatively
Postoperative Opioid Consumption (Morphine Milligram Equivalents)
Periodo de tiempo: Perioperative/Periprocedural; 3 months postoperatively

Postoperative Opioid Consumption (Morphine Milligram Equivalents):

Total postoperative opioid use following primary total knee arthroplasty, calculated as cumulative morphine milligram equivalents (MME) administered during hospitalization and follow-up. This is a continuous variable (≥0 mg), where higher values indicate greater opioid consumption (worse outcome).

Perioperative/Periprocedural; 3 months postoperatively
Postoperative Medical Complications
Periodo de tiempo: Perioperative/Periprocedural

Postoperative Medical Complications:

Occurrence of medical complications following primary total knee arthroplasty, including myocardial infarction, venous thromboembolism, cerebrovascular accident, acute kidney injury, respiratory failure, urinary tract infection, pneumonia, gastrointestinal obstruction, and need for intensive care unit (ICU) admission during the same hospitalization. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.

Perioperative/Periprocedural
Postoperative Surgical Complications
Periodo de tiempo: Perioperative/Periprocedural; 3 months postoperatively
Occurrence of surgical complications following primary total knee arthroplasty, including reoperation, periprosthetic fracture, dislocation, infection, and postoperative stiffness. This is a composite dichotomous outcome (Yes/No), where "Yes" indicates that one or more complications occurred and represents a worse outcome.
Perioperative/Periprocedural; 3 months postoperatively

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Nicholas M Hernandez, MD, University of Washington

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de junio de 2026

Finalización primaria (Estimado)

1 de junio de 2028

Finalización del estudio (Estimado)

1 de junio de 2028

Fechas de registro del estudio

Enviado por primera vez

1 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

13 de mayo de 2026

Publicado por primera vez (Actual)

20 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

20 de mayo de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

13 de mayo de 2026

Última verificación

1 de mayo de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

producto fabricado y exportado desde los EE. UU.

Sí

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir